Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
Globe Newswire•27/10/2026•09:30 ET
0
Key Highlights
- ➤15-month median response duration exceeds retifanlimab’s historical 9.5 months
- ➤100% of responding patients survived beyond 12 months
- ➤FDA Fast Track and guidance support potential SCAC registration
- ➤Oncolytics plans potential checkpoint-inhibitor studies in anal cancer
- ➤Pelareorep may expand into HPV-associated head and neck cancer
Expert Statements
Jared Kelly, Chief Executive Officer of Oncolytics
“We see anal cancer as the starting point for building a pelareorep plus checkpoint inhibitor platform across HPV-driven cancers.”
Jared Kelly, Chief Executive Officer of Oncolytics
“Our survival data and recent FDA regulatory clarity give us a path to pursue registration in anal cancer while expanding into other HPV-associated tumors, including head and neck cancer, where pelareorep has already demonstrated encouraging clinical activity.”
GOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results for approved second-line checkpoint inhibitor monotherapy
100% of responding patients survived for longer than one year
Get started
Create a free account to read the full story.